Benefit-Risk Analysis for Decision-Making: An Approach.

about

A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma.

P2860

Q50122392-3C30EAA8-E8AD-4407-863C-837BADD171E7

P2860

Benefit-Risk Analysis for Decision-Making: An Approach.

Item

http://www.wikidata.org/entity/Q48770147

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Benefit-Risk Analysis for Decision-Making: An Approach.

@en

Benefit-Risk Analysis for Decision-Making: An Approach.

@nl

type

Item

label

Benefit-Risk Analysis for Decision-Making: An Approach.

@en

Benefit-Risk Analysis for Decision-Making: An Approach.

@nl

prefLabel

Benefit-Risk Analysis for Decision-Making: An Approach.

@en

Benefit-Risk Analysis for Decision-Making: An Approach.

@nl

P1476

Benefit-Risk Analysis for Decision-Making: An Approach.

@en

P2093

G K Raju

http://www.w3.org/2001/XMLSchema#string

K Gurumurthi

http://www.w3.org/2001/XMLSchema#string

R Domike

http://www.w3.org/2001/XMLSchema#string

P2860

Approval of a Tuberculosis Drug Based on a Paradoxical Surrogate Measure

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.

Multi-state models for the analysis of time-to-event data.

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.

Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.

P304

654-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.507

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27627788

http://www.w3.org/2001/XMLSchema#string

Benefit-Risk Analysis for Decision-Making: An Approach.

about

P2860

P2860

Benefit-Risk Analysis for Decision-Making: An Approach.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698